Bevacizumab biosimilar (BioIntegrator)

贝伐单抗生物类似药 (BioIntegrator)

Report date: 2024/08/30 09:58:16

Base Information

Drug NameBevacizumab biosimilar (BioIntegrator)
Drug Alias NameBI-MAB-02
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBiointegrator Llc
China Registration ClassN/A

Develop Information

Active CompaniesBiointegrator Llc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A